for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Xenon Pharmaceuticals Inc

XENE.OQ

Latest Trade

11.19USD

Change

-0.33(-2.86%)

Volume

13,353

Today's Range

11.09

 - 

11.60

52 Week Range

7.00

 - 

18.38

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
11.52
Open
11.60
Volume
13,353
3M AVG Volume
2.24
Today's High
11.60
Today's Low
11.09
52 Week High
18.38
52 Week Low
7.00
Shares Out (MIL)
34.99
Market Cap (MIL)
403.28
Forward P/E
-12.95
Dividend (Yield %)
--

Next Event

Xenon Pharmaceuticals Inc Annual Shareholders Meeting

Latest Developments

More

Xenon Pharmaceuticals Reports Third Quarter 2020 Financial Results And Provides Corporate Update

Xenon Pharmaceuticals Receives FDA Feedback And Is On Track To Initiate Phase 3 Clinical Trial For The Treatment Of Kcnq2-Dee

Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results And Provides Corporate Update

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.

Industry

Biotechnology & Drugs

Contact Info

3650 Gilmore Way

BURNABY, BC

V5G 4W8

Canada

+1.604.4843300

http://www.xenon-pharma.com/

Executive Leadership

Michael M. Tarnow

Independent Chairman of the Board

Ian C. Mortimer

President, Chief Financial Officer, Corporate Secretary

Simon Neil Pimstone

Chief Executive Officer, Director

Robin Paul Sherrington

Executive Vice President - Strategy & Innovation

Shelley McCloskey

Senior Vice President - Human Resources

Key Stats

1.25 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-1.710

2018

-1.630

2019

-1.540

2020(E)

-0.864
Price To Earnings (TTM)
--
Price To Sales (TTM)
13.29
Price To Book (MRQ)
2.31
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-20.70
Return on Equity (TTM)
-18.72

Latest News

Latest News

BRIEF-Xenon Pharmaceuticals Files For Mixed Shelf Of Upto $250 Mln - SEC Filing

* XENON PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $250 MILLION - SEC FILING Source text: https://bit.ly/2U5tKOV Further company coverage:

BRIEF-Xenon Pharmaceuticals Posts Quarterly Loss Per Share $0.22

* XENON PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Xenon Pharma Provides Corporate Update In The Context Of Covid-19

* XENON PHARMACEUTICALS PROVIDES CORPORATE UPDATE IN THE CONTEXT OF COVID-19

BRIEF-Xenon Pharmaceuticals Expects FDA Feedback On Phase 3 Protocol For XEN496 Early Within Q2

* XENON PHARMACEUTICALS REPORTS 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Xenon Presents Positive Xen1101 Tms Pharmacodynamic Phase 1 Data At 14Th Eilat Conference

* XENON PRESENTS POSITIVE XEN1101 TMS PHARMACODYNAMIC PHASE 1 DATA AT 14TH EILAT CONFERENCE

BRIEF-Xenon Pharmaceuticals Q1 Net Loss Per Common Share $0.21

* XENON PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Xenon Pharmaceuticals Enters Into At-The-Market Equity Offering Sales Agreement With Stifel, Nicolaus & Co

* XENON PHARMACEUTICALS INC - ON MAY 8, CO ENTERED INTO AN AT--MARKET EQUITY OFFERING SALES AGREEMENT WITH STIFEL, NICOLAUS & COMPANY - SEC FILING

BRIEF-Xenon Pharmaceuticals To Host Conference Call To Discuss Q1 2018 Financial Results

* XENON PHARMACEUTICALS TO HOST CONFERENCE CALL AND WEBCAST TO DISCUSS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE Source text for Eikon: Further company coverage:

BRIEF-Xenon Pharma, Teva Pharma Terminate Development & License Agreement

* XENON PHARMACEUTICALS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Xenon Advances Second Proprietary Epilepsy Product Into Clinic With Initiation Of Xen901 Phase 1 Clinical Trial

* XENON PHARMACEUTICALS ADVANCES SECOND PROPRIETARY EPILEPSY PRODUCT INTO THE CLINIC WITH INITIATION OF XEN901 PHASE 1 CLINICAL TRIAL Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Xenon Pharmaceuticals Expects To Have Ongoing XEN1101 Phase 1 Clinical Trial Completed By Mid-Year

* XENON PHARMACEUTICALS INC - EXPECT TO HAVE ONGOING XEN1101 PHASE 1 CLINICAL TRIAL COMPLETED BY MID-YEAR

BRIEF-Xenon Pharma Says Entered Into Loan And Security Agreement With Silicon Valley Bank

* XENON PHARMACEUTICALS- ON DEC 18, CO, UNIT ENTERED INTO LOAN AND SECURITY AGREEMENT WITH SILICON VALLEY BANK - SEC FILING

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up